SciBase Secures Financial Backing for Ongoing Rights Issue Amid Future Investments
On September 25, 2026, SciBase Holding AB, a prominent player in the medical technology sector, announced that it has received a binding commitment from Bergs Securities AB. This commitment pertains to a significant financial backing for SciBase's ongoing rights issue, which aims to raise approximately SEK 57.5 million.
The announcement reveals that Bergs Securities has fulfilled its previous letter of intent, thereby pledging around SEK 24.2 million, which represents about 42% of the target amount for the rights issue. The remaining amount has been covered by subscription undertakings from several existing shareholders, bringing the total coverage to 100%. This collective financial support includes commitments from notable stakeholders such as Ribbskottet AB and Castle Biosciences Inc, ensuring the success of the offering.
The subscription price for the rights issue has been set at SEK 15 per share. Shareholders registered in the Euroclear Nordics AB share register as of September 10, 2026, received one subscription right for each share held, paving the way for them to acquire three new shares for every eight rights they possess. The subscription period spans from September 15 to September 29, 2026, during which existing shareholders can exchange their rights for shares in the company.
Investors trading in subscription rights on the Nasdaq First North Growth Market were able to do so until September 24, 2026, with trading in BTA (paid subscribed shares) continuing until around October 16, 2026. Results from the rights issue are anticipated to be disclosed on or about October 1, 2026.
Advisers for the rights issue include Bergs Securities and Birchtree Advisory as financial advisors, with BAHR offering legal counsel. A notable aspect of the guarantee commitment is its structure, as it is not secured by traditional bank guarantees or pledges, giving an unsecured, yet optimistic outlook on the financial strategy of SciBase.
The heightened financial support comes at a pivotal time for SciBase, a company at the cutting edge of AI-powered dermatological solutions. With its flagship product Nevisense, SciBase endeavors to provide advanced diagnostic tools that enhance the accuracy of skin cancer detection, ultimately aiming to improve patient outcomes and mitigate healthcare costs.
SciBase's strategy is deeply rooted in research conducted at Stockholm's prestigious Karolinska Institutet, which has over two decades of history contributing to the field of dermatology. This innovative approach not only symbolizes a forward-thinking methodology in healthcare but also positions SciBase prominently within the global medical technology landscape.
As the company embarks on this crucial rights issue, stakeholders remain optimistic about the potential impact of the funds raised, which are seen as essential for bolstering SciBase's growth trajectory and fostering further advances in skin health management technologies. Investors are closely monitoring the situation, particularly considering the intrinsic value that lies within the company's pioneering use of technology backed by solid medical research.
In conclusion, the successful confirmation of Bergs Securities' guarantee commitment signals a strong market confidence in SciBase's future endeavors. As the company proceeds with its rights issue, it stands poised to leverage this financial support to enhance its offerings and expand its market reach. With a dedicated focus on reducing patient suffering and empowering physicians, SciBase not only aims to transform the dermatology sector but also promises to drive significant value for its investors as it solidifies its position in the industry.
The announcement reveals that Bergs Securities has fulfilled its previous letter of intent, thereby pledging around SEK 24.2 million, which represents about 42% of the target amount for the rights issue. The remaining amount has been covered by subscription undertakings from several existing shareholders, bringing the total coverage to 100%. This collective financial support includes commitments from notable stakeholders such as Ribbskottet AB and Castle Biosciences Inc, ensuring the success of the offering.
The subscription price for the rights issue has been set at SEK 15 per share. Shareholders registered in the Euroclear Nordics AB share register as of September 10, 2026, received one subscription right for each share held, paving the way for them to acquire three new shares for every eight rights they possess. The subscription period spans from September 15 to September 29, 2026, during which existing shareholders can exchange their rights for shares in the company.
Investors trading in subscription rights on the Nasdaq First North Growth Market were able to do so until September 24, 2026, with trading in BTA (paid subscribed shares) continuing until around October 16, 2026. Results from the rights issue are anticipated to be disclosed on or about October 1, 2026.
Advisers for the rights issue include Bergs Securities and Birchtree Advisory as financial advisors, with BAHR offering legal counsel. A notable aspect of the guarantee commitment is its structure, as it is not secured by traditional bank guarantees or pledges, giving an unsecured, yet optimistic outlook on the financial strategy of SciBase.
The heightened financial support comes at a pivotal time for SciBase, a company at the cutting edge of AI-powered dermatological solutions. With its flagship product Nevisense, SciBase endeavors to provide advanced diagnostic tools that enhance the accuracy of skin cancer detection, ultimately aiming to improve patient outcomes and mitigate healthcare costs.
SciBase's strategy is deeply rooted in research conducted at Stockholm's prestigious Karolinska Institutet, which has over two decades of history contributing to the field of dermatology. This innovative approach not only symbolizes a forward-thinking methodology in healthcare but also positions SciBase prominently within the global medical technology landscape.
As the company embarks on this crucial rights issue, stakeholders remain optimistic about the potential impact of the funds raised, which are seen as essential for bolstering SciBase's growth trajectory and fostering further advances in skin health management technologies. Investors are closely monitoring the situation, particularly considering the intrinsic value that lies within the company's pioneering use of technology backed by solid medical research.
In conclusion, the successful confirmation of Bergs Securities' guarantee commitment signals a strong market confidence in SciBase's future endeavors. As the company proceeds with its rights issue, it stands poised to leverage this financial support to enhance its offerings and expand its market reach. With a dedicated focus on reducing patient suffering and empowering physicians, SciBase not only aims to transform the dermatology sector but also promises to drive significant value for its investors as it solidifies its position in the industry.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.